DRL-Header DRL-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            ALK

            • Deals

            Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

            Lead Product(s): Epinephrine Bitartrate

            Therapeutic Area: Immunology Product Name: Jext

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Grandpharma

            Deal Size: $14.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 30, 2021

            Details:

            Jext® is expected to be the first AAI to market in China. Prior to registration in mainland China, Grandpharma plans to start selling Jext® in southern China under a special licence linked to the existing registration of Jext® in Hong Kong.